Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Complementary Biomolecular Analysis Instruments Available for Research and Clinical Labs

By BiotechDaily International staff writers
Posted on 31 Mar 2014
Image: b-screen is a versatile biomolecular interaction analysis tool for biomolecular arrays in standard microscope format (Photo courtesy of Biametrics GmbH).
Image: b-screen is a versatile biomolecular interaction analysis tool for biomolecular arrays in standard microscope format (Photo courtesy of Biametrics GmbH).
Two new instruments for biomolecular analysis feature coated sensor chips (microarray format and mini format respectively) and assay protocols ready to support almost any research and development application from kinetic evaluation of microarrays to online immobilization.

The instruments—b-screen and b-portable—are products of Biametrics GmbH (Tübingen, Germany). Biametrics develops and markets label-free analytical system solutions for life science applications.

Biametrics has recently launched two new product lines intended to facilitate research in diverse types of life science laboratories. The b-screen device is able to handle any standard microarray format and can detect up to 10,000 bimolecular interactions in a single measurement. The b-portable device enables high quality label-free interaction analysis under laboratory or field conditions using a smart and inexpensive technology platform.

Current applications for b-screen include bioanalytics, drug discovery, production, and quality control. Based on the same technology, b-portable is a point-of-care device for early cancer and infection detection.

The b-screen instrument provides label-free read-out of up to 10,000 spots per square centimeter. It utilizes a precise and automated microfluidics system for incubation of the microarray with the sample of interest. The instrument can be used with multiple array layouts, uses glass or plastic type substrates, and is compatible with almost any common microarray printer. No fluorescence labels are needed, which leads to assay conditions similar to the in -vivo situation combined with minimal sample pretreatment and minimized reagent consumption.

Both b-screen and b-portable may be used with different sample types such as serum or whole blood or other relevant complex matrices such as cell culture medium. Kinetic data can be obtained for almost any kind of biomolecular interaction such as those between proteins, between peptides and proteins, and between small molecules and proteins.

“With b-screen users are able to easily transfer existing microarrays directly into a label-free assay format thus gaining additional information on kinetics and thermodynamics at high precision and reliability,” said Günther Proll, managing director of Biametrics. “The device allows very low cost high-throughput screening and the applications we have established demonstrate excellent performance and outcome characteristics. We believe b-screen provides key advantages over current options like surface plasmon resonance (SPR).”

Related Links:

Biametrics GmbH



WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Mosquitoes are known to infect people and animals with West Nile virus. Studying West Nile virus infection in mice, researchers have shown that the antiviral compound interferon-lambda tightens the blood-brain barrier, making it harder for the virus to invade the brain (Photo courtesy of the CDC – [US] Centers for Disease Control and Prevention).

Interferon-Lambda Prevents West Nile Virus from Crossing the Blood-brain Barrier

The cytokine interferon-lambda prevents West Nile virus from infecting brain cells by reducing transport of large molecules across the blood-brain barrier. Although interferon-lambda [also known as... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

27 May 2015 - 28 May 2015
02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.